Upcoming News Article: Adtralza Treatment for Atopic Eczema

A Closer Look at Adtralza

Adtralza is the first monoclonal antibody approved for the treatment of moderate to severe atopic eczema in adults and children over 12 years of age. Atopic eczema is a common chronic inflammatory skin condition that affects millions of people worldwide.

How Adtralza Works

Adtralza binds to interleukin-13 (IL-13), a key cytokine involved in the inflammatory process of atopic eczema. By blocking IL-13, Adtralza reduces inflammation and itch, providing significant relief to patients with moderate to severe eczema.